Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Westlake Aldringskohorte (WeAC)

5. november 2026 opdateret af: Westlake University

Westlake Alderskohorte

The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.

Studieoversigt

Detaljeret beskrivelse

The investigators will recruit middle-aged and aged participants, including healthy controls and individuals with neurodegenerative disorders such as mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB), etc. The aim of this study is to construct a longitudinal database that includes sociodemographic, lifestyle, clinical, neuroimaging, and multi-omics data. This database will be used to characterize the molecular signatures of neurodegenerative disorders. In addition, the investigators will identify biomarkers associated with neurodegenerative diseases. Furthermore, the investigators aim to uncover the mechanisms underlying the progression of mild cognitive impairment (MCI) and other neurodegenerative disorders.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

2800

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310058
        • Rekruttering
        • Hangzhou First People's Hospital
        • Kontakt:
      • Hangzhou, Zhejiang, Kina, 310058
        • Rekruttering
        • Hangzhou Third People's Hospital
        • Kontakt:
          • Peng Li, Master
        • Kontakt:
          • Yu Chen, Master

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

55 år til 90 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

All participants must be Chinese residents, regardless of their ethnicity.

Beskrivelse

Inclusion Criteria:

  1. Age between 55 and 90 years (inclusive) at baseline.
  2. Availability of a companion capable of providing independent functional assessments and fluent in Chinese.
  3. Willingness and ability to regularly complete required surveys and physical examinations as per study protocol.
  4. MMSE scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB/PDD patients.
  5. Healthy controls: CDR = 0, memory box = 0. MCI: CDR = 0.5, memory box ≥ 0.5. AD: CDR = 0.5 or 1. The DLB/PDD meets the core features of diagnosis.
  6. Healthy controls exhibit no significant cognitive or functional decline. Patients with MCI have objective cognitive impairment not sufficient for an AD diagnosis. AD patients fulfill the NINCDS-ADRDA criteria. DLB/PDD patients meet their respective international consensus diagnostic criteria. Other neurodegenerative diseases meet the diagnostic criteria.

Exclusion Criteria:

  1. Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy.
  2. Current use of psychoactive medications or any other drugs that may affect the study.
  3. Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body.
  4. Participants with any other diseases that may affect the study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Cognitive function
Tidsramme: 48 months

Cognitive function will be evaluated using the Mini-Mental State Examination (MMSE, score range: 0-30, with higher scores indicating better cognitive function) and clinical diagnosis provided by physicians.

48 months
Gut microbiome
Tidsramme: 48 months

The gut microbiome will be profiled by metagenomic sequencing or ITS rRNA sequencing. In addition, fecal microbiota will be cultured, isolated, and identified.

48 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Brain magnetic resonance imaging
Tidsramme: 48 months

Use brain magnetic resonance imaging (MRI) to measure the brain structure and function of participants.

48 months
Positron emission tomography
Tidsramme: 48 months

Assess the brain function and neurological disorders by positron emission tomography (PET).

48 months
Brain images relevant inspections
Tidsramme: 48 months

Other brain image relevant inspections required for study to measure brain structure and function of participants.

48 months
Electroencephalogram
Tidsramme: 48 months

Electroencephalogram (EEG) monitors the electrical activity of the brain. And further measure based on coupled EEG/MEG and eye-tracking.

48 months
Blood biochemical parameters
Tidsramme: 48 months

Blood biochemical parameters, including glucose and lipids, will be analyzed using an automated biochemical analyzer.

48 months
Serum inflammatory factors
Tidsramme: 48 months

Detect and assess serum inflammatory factors such as IL-1β, IL-6, and IL-12, in serum from participants.

48 months
Health and behavior monitoring
Tidsramme: 48 months

Use fitness trackers to record the physiological and behavioral data of participants.

48 months
Sleep data measurement
Tidsramme: 48 months

Use the polysomnography (PSG) to record the sleep data of participants to evaluate the sleep quality.

48 months
Continuous glucose monitoring
Tidsramme: 48 months

Use the continuous glucose monitoring (CGM) for dynamic blood glucose recording to determine the glycemic control of participants.

48 months
Environmental measurement
Tidsramme: 48 months

Use the environmental monitoring device to measure various exposure factors in the participants' living environment.

48 months
Multi-omics data
Tidsramme: 48 months

Multi omics results of detecting biological samples such as plasma, peripheral blood mononuclear cells (PBMCs), urine, feces, saliva, etc.

48 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Ju-Sheng Zheng, PhD, Westlake University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

3. juni 2026

Primær færdiggørelse (Anslået)

31. december 2030

Studieafslutning (Anslået)

31. december 2031

Datoer for studieregistrering

Først indsendt

24. december 2025

Først indsendt, der opfyldte QC-kriterier

19. januar 2026

Først opslået (Faktiske)

28. januar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 20251023ZJS001

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner